A large, real-world study presented at the AACE Annual Meeting found that adults with osteoporosis prescribed denosumab (Prolia) have no increased long-term risk of atypical femur fractures (AFF) compared to those using bisphosphonates.
ORTHOPEDICSPHARMACOLOGY < class="penci-entry-title entry-title grid-title penci_grid_title">Denosumab does not raise atypical femur fracture risk